Imaging suggests tirzepatide boosts brown fat to aid weight loss
TL;DR
In a 24-week trial, tirzepatide significantly increased brown adipose tissue activity and volume on PET/CT and MRI compared with placebo (about 65% vs 41%), suggesting the GLP-1 drug may boost energy expenditure and promote white-to-beige fat conversion, contributing to weight loss beyond appetite suppression.
Topics:healthhealth-and-science#brown-adipose-tissue#glp-1#health-and-science#imaging#tirzepatide#weight-loss
Want the full story? Read the original reporting
Read on Radiology Business